Financial Results Approval

The Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The financial results were reviewed by the statutory auditors, Deloitte Haskins & Sells LLP, who issued an unmodified conclusion.

Standalone Financial Performance (Q2 FY27)

  • Revenue from operations: ₹8,321 million (Q2 FY26: ₹6,996 million)
  • Other income: ₹339 million (Q2 FY26: ₹228 million)
  • Total income: ₹8,660 million (Q2 FY26: ₹7,224 million)
  • Profit before tax: ₹2,409 million (Q2 FY26: ₹1,948 million)
  • Tax expense: ₹612 million (Q2 FY26: ₹491 million)
  • Net profit: ₹1,797 million (Q2 FY26: ₹1,457 million), representing 27.4% YoY growth
  • Earnings per share (basic): ₹10.75 (Q2 FY26: ₹8.73)
  • Earnings per share (diluted): ₹10.73 (Q2 FY26: ₹8.72)

Half-Year Standalone Performance (H1 FY27)

  • Revenue from operations: ₹15,965 million (H1 FY26: ₹13,403 million)
  • Other income: ₹638 million (H1 FY26: ₹491 million)
  • Total income: ₹16,603 million (H1 FY26: ₹13,894 million)
  • Profit before tax: ₹4,632 million (H1 FY26: ₹3,672 million)
  • Tax expense: ₹1,176 million (H1 FY26: ₹922 million)
  • Net profit: ₹3,456 million (H1 FY26: ₹2,750 million)
  • Earnings per share (basic): ₹20.69 (H1 FY26: ₹16.48)
  • Earnings per share (diluted): ₹20.64 (H1 FY26: ₹16.45)

Consolidated Financial Performance (Q2 FY27)

  • Revenue from operations: ₹8,739 million (Q2 FY26: ₹7,306 million)
  • Other income: ₹343 million (Q2 FY26: ₹248 million)
  • Total income: ₹9,082 million (Q2 FY26: ₹7,554 million)
  • Profit before tax: ₹2,605 million (Q2 FY26: ₹2,036 million)
  • Tax expense: ₹666 million (Q2 FY26: ₹514 million)
  • Net profit: ₹1,939 million (Q2 FY26: ₹1,522 million)
  • Earnings per share (basic): ₹11.51 (Q2 FY26: ₹9.03)
  • Earnings per share (diluted): ₹11.47 (Q2 FY26: ₹9.01)

Half-Year Consolidated Performance (H1 FY27)

  • Revenue from operations: ₹16,716 million (H1 FY26: ₹14,004 million)
  • Other income: ₹662 million (H1 FY26: ₹529 million)
  • Total income: ₹17,378 million (H1 FY26: ₹14,533 million)
  • Profit before tax: ₹4,892 million (H1 FY26: ₹3,847 million)
  • Tax expense: ₹1,248 million (H1 FY26: ₹985 million)
  • Net profit: ₹3,644 million (H1 FY26: ₹2,862 million)
  • Earnings per share (basic): ₹21.65 (H1 FY26: ₹16.97)
  • Earnings per share (diluted): ₹21.61 (H1 FY26: ₹16.94)

Dividend Declaration

The Board declared a second interim dividend of ₹5 per equity share (50% on face value of ₹10 each) for FY 2026-27. The record date for payment is November 11, 2026, and the dividend will be paid within 30 days of declaration.

Director Appointment

Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Ms. Vasuta Agarwal (DIN: 07480674) as an Additional Director designated as Non-Executive Independent Director for a term of three consecutive years commencing November 4, 2026, subject to shareholder approval through postal ballot.

Ms. Agarwal's profile includes:

  • Chief Revenue Officer at Gnani.ai
  • Experience in artificial intelligence, digital advertising, strategy and business operations
  • Previous roles at InMobi, McKinsey & Company, and Intel
  • PGDM from IIM Bangalore and engineering degree from BITS Pilani
  • Board positions at IndiaMART InterMESH Limited, Kaya Limited, Iglulabs Software Private Limited, and Valetez Services Private Limited
  • Recognized in Economic Times 40 Under Forty list and other industry awards

Subsidiary Investment

The Board approved further investment of up to ₹49.5 crore in Dr. Lal PathLabs FZCO (LPL Dubai), a wholly-owned subsidiary, in one or more tranches. The investment is for meeting business and operational requirements, including making further investment in its subsidiary Sunshine Healthcare Limited (SHL), Ghana.

Details of LPL Dubai:

  • Incorporated on June 12, 2026, in Dubai, UAE
  • Wholly-owned subsidiary of Dr. Lal PathLabs Limited
  • Established for strategic investments in diagnostics and allied activities

Details of SHL, Ghana:

  • Incorporated on September 7, 2010
  • Turnover: FY26 ₹244 million, FY25 ₹240 million, FY24 ₹217 million
  • Engaged in healthcare diagnostics services

The investment constitutes a related party transaction but will be conducted at arm's length. The transaction is expected to be completed by March 31, 2027.

Corporate Actions and Acquisitions

The document details several acquisitions and investments made during H1 FY27:

1. Acquired 100% stake in Shahbazkers Diagnostic Centre Private Limited on May 1, 2026, for ₹200 million, resulting in goodwill of ₹143 million

2. Incorporated Dr. Lal PathLabs FZCO in Dubai on June 12, 2026, with investment of AED 19 million

3. Invested ₹77.5 million in Dr. Lal Ventures Private Limited through additional equity subscription

4. Acquired 80% stake in Sunshine Healthcare Limited, Ghana, for consideration not exceeding GHS 57 million, resulting in goodwill of ₹239 million

5. Subscribed to 30% equity in Neuome Technologies Private Limited on August 27, 2026, for ₹35 million

6. Acquired 70% stake in SN Genelab Private Limited on October 1, 2026, for up to ₹1,680 million plus performance-linked earn-out capped at ₹315 million

7. Subsequent to September 30, 2026, invested additional ₹303 million in Pathlabs Unifiers Private Limited

ESOP Issuance

During Q2 and H1 FY27, the company issued 211,050 and 293,800 equity shares respectively to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022.

Board Meeting Details

The Board meeting commenced at 11:49 AM IST and concluded at 1:20 PM IST on November 4, 2026.